DVA · Davita Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $13.64B | $12.82B | $12.14B | $11.61B | $11.62B | $11.55B |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $1.67B | $1.54B | $1.47B | $1.36B | $1.20B | $1.25B |
| Total Operating Expenses | $11.60B | $10.73B | $10.54B | $10.27B | $9.82B | $9.86B |
| D&A | $708.25M | $716.40M | $736.47M | $721.13M | $667.75M | $616.63M |
| Operating Income | $2.04B | $2.09B | $1.60B | $1.34B | $1.80B | $1.69B |
| Interest Expense | $539.92M | $435.20M | $373.95M | $339.25M | $267.05M | $282.93M |
| Income Tax | $293.11M | $279.66M | $220.12M | $198.09M | $306.73M | $313.93M |
| Net Income | $746.80M | $936.34M | $691.53M | $560.40M | $978.45M | $773.64M |
| EPS - Basic | $10.06 | $11.02 | $7.62 | $6.03 | $9.30 | $6.46 |
| EPS - Diluted | $9.84 | $10.73 | $7.42 | $5.85 | $8.90 | $6.31 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $676.44M | $794.93M | $380.06M | $244.09M | $461.90M | $324.96M |
| Accounts Receivable | $2.41B | $2.15B | $1.99B | $2.13B | $1.96B | $1.82B |
| Inventory | $160.63M | $134.56M | $143.10M | $109.12M | $107.43M | $111.63M |
| Accounts Payable | $696.15M | $547.20M | $514.53M | $479.78M | $402.05M | $434.25M |
| Current Assets | $4.06B | $3.75B | $3.14B | $3.16B | $3.17B | $3.15B |
| Total Assets | $17.48B | $17.29B | $16.89B | $16.93B | $17.12B | $16.99B |
| Current Liabilities | $3.14B | $2.97B | $2.64B | $2.62B | $2.40B | $2.48B |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $16.32B | $15.19B | $14.15B | $14.70B | $14.75B | $14.09B |
| Stockholders' Equity | ($651.08M) | $121.12M | $1.06B | $712.33M | $755.51M | $1.38B |
| Retained Earnings | ($328.43M) | $1.53B | $598.29M | $174.49M | $354.34M | $852.54M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.89B | $2.02B | $2.06B | $1.56B | $1.93B | $1.98B |
| Investing Cash Flow | ($654.95M) | ($771.43M) | ($771.80M) | ($630.35M) | ($784.73M) | ($825.37M) |
| Financing Cash Flow | ($1.37B) | ($816.94M) | ($1.17B) | ($1.12B) | ($1.08B) | ($1.85B) |
| CapEx | $575.86M | $555.44M | $567.99M | $603.43M | $641.47M | $674.54M |
| Free Cash Flow | $1.31B | $1.47B | $1.49B | $961.14M | $1.29B | $1.30B |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | 15.0% | 16.3% | 13.2% | 11.5% | 15.5% | 14.7% |
| EBITDA margin | 20.2% | 21.9% | 19.3% | 17.7% | 21.2% | 20.0% |
| Net margin | 5.5% | 7.3% | 5.7% | 4.8% | 8.4% | 6.7% |
| Free cash flow margin | 9.6% | 11.4% | 12.3% | 8.3% | 11.1% | 11.3% |
| FCF / Net income | 1.75 | 1.57 | 2.16 | 1.72 | 1.32 | 1.69 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 12.3% | 12.0% | 12.1% | 11.7% | 10.3% | 10.8% |
| Effective tax rate | 28.2% | 23.0% | 24.1% | 26.1% | 23.9% | 28.9% |
| Return on assets | 4.3% | 5.4% | 4.1% | 3.3% | 5.7% | 4.6% |
| Return on equity | -114.7% | 773.1% | 65.5% | 78.7% | 129.5% | 55.9% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.29 | 1.26 | 1.19 | 1.20 | 1.32 | 1.27 |
| Quick ratio | 1.24 | 1.21 | 1.13 | 1.16 | 1.28 | 1.23 |
| Cash ratio | 0.22 | 0.27 | 0.14 | 0.09 | 0.19 | 0.13 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | 3.8x | 4.8x | 4.3x | 3.9x | 6.7x | 6.0x |
| Equity multiplier | -26.85 | 142.71 | 16.00 | 23.76 | 22.66 | 12.28 |
| Liabilities / Assets | 0.93 | 0.88 | 0.84 | 0.87 | 0.86 | 0.83 |
| Efficiency | ||||||
| Asset turnover | 0.78 | 0.74 | 0.72 | 0.69 | 0.68 | 0.68 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 65d | 61d | 60d | 67d | 61d | 58d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 11.5x | 13.9x | 14.1x | 12.8x | 12.8x | 18.6x |
| P / B | - | 107.8x | 9.2x | 10.0x | 16.6x | 10.4x |
| P / S | 0.6x | 1.0x | 0.8x | 0.6x | 1.1x | 1.2x |
| EV / EBITDA | 2.9x | 4.4x | 4.0x | 3.4x | 4.9x | 6.1x |
| Growth | ||||||
| Revenue growth (YoY) | 6.5% | 5.6% | 4.6% | -0.1% | 0.6% | 1.4% |
| Revenue CAGR (3y) | 5.5% | 3.3% | 1.7% | 0.6% | 2.8% | - |
| Revenue CAGR (5y) | 3.4% | 2.4% | 2.5% | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -2.2% | 30.4% | 19.7% | -25.5% | 6.1% | 3.1% |
| Net income growth (YoY) | -20.2% | 35.4% | 23.4% | -42.7% | 26.5% | -4.6% |
| EPS growth (YoY) | -8.3% | 44.6% | 26.8% | -34.3% | 41.0% | 19.7% |
| EPS CAGR (3y) | 18.9% | 6.4% | 5.5% | 3.5% | 113.1% | 22.1% |
| EPS CAGR (5y) | 9.3% | 15.3% | 51.8% | 11.0% | 15.7% | 38.2% |
| FCF growth (YoY) | -10.6% | -1.6% | 55.1% | -25.5% | -1.2% | -0.1% |
| FCF CAGR (5y) | 0.1% | 2.3% | 13.7% | -1.9% | 2.6% | 11.7% |
| Book value growth (YoY) | - | -88.5% | 48.3% | -5.7% | -45.4% | -35.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$13.64B totalUSDialysis And Related Lab Services With Intersegment$11.79B · 86.4%
Other Operating Segments With Intersegment$1.92B · 14.1%
All Other Segments($11.20M) · -0.1%
USDialysis And Related Lab Services($60.96M) · -0.4%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.15
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Misc Health & Allied Services, NEC
Comparing DAVITA INC. against the 5 most active filers in the same SIC group.